nach oben

International Urogynecology Journal

Erschienen in:

02.05.2023 | Review Article

Current status of patient-reported outcome measures and other subjective assessment grading tools in bladder pain syndrome

verfasst von: Sabine Uguzova, Patrick Juliebø-Jones, Christian Beisland, Ahsanul Haq

Erschienen in: International Urogynecology Journal | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

Bladder pain syndrome (BPS) is characterised by chronic pain in the bladder area accompanied by urgency and/or frequency without the presence of other confusable diseases. Owing to a lack of gold standard diagnostic tests and definitive cure it is paramount to define treatment goals and validated measurements of outcomes. Patient-reported outcome measures (PROMs) are validated questionnaires completed by patients that can help to reduce ambiguity in the BPS patient treatment pathway, but they are currently underutilised. We present to our knowledge the first summary and analysis of all available PROMs in BPS patients.

Methods

Review and critical evaluation of all relevant BPS guidelines presented in English language and a systematic search for PubMed database articles relating to PROMs and subjective assessment grading tools in BPS, interstitial cystitis and chronic pelvic pain syndrome.

Results

The ideal PROMs for BPS should assess urinary symptoms, pain, quality of life and sexual health. There are five PROMs designed specifically for BPS patients. The most universally used and quoted is the O’Leary–Sant questionnaire followed by the Pelvic Pain and Urgency Score and the Wisconsin Interstitial Cystitis scale. However, there is no single PROM for BPS that is ideal, and for comprehensive assessment several questionnaires are often used simultaneously.

Conclusions

Patient-reported outcome measures are a valuable tool for use in the long-term management of patients burdened with BPS. There are now several disease-specific PROMs in use that have their respective advantages and disadvantages. Their use should be encouraged in future research as well as continued efforts to develop new PROMs that can address current shortcomings.

Malde S, Palmisani S, Al-Kaisy A, Sahai A. Guideline of guidelines: bladder pain syndrome. BJU Int. 2018;122:729–43. https://doi.org/10.1111/bju.14399.CrossRefPubMed

Engler DS, Baranowski AP. EAU Guidelines on “Chronic Pelvic Pain”. EAU Guidelines Office, Arnhem, The Netherlands. Edn. presented at the EAU Annual Congress Amsterdam 2022.

Juliebø-Jones P, Hjelle KM, Mohn J, et al. Management of bladder pain syndrome (BPS): a practical guide. Adv Urol. 2022;2022:1–9. https://doi.org/10.1155/2022/7149467.CrossRef

Jones P, Hjelle KM, Mohn J, et al. Current Status of Intravesical Therapies for Bladder Pain Syndrome (BPS): A Narrative Review of Emerging Evidence. Urol. 2021;156:e48–57. https://doi.org/10.1016/j.urology.2021.05.042.CrossRefPubMed

Wu A, Snyder C. Getting ready for patient-reported outcomes measures (PROMs) in clinical practice. Healthc Pap. 2012;11:48–53. https://doi.org/10.12927/hcpap.2012.22705.CrossRef

Kluzek S, Dean B, Wartolowska KA. Patient-reported outcome measures (PROMs) as proof of treatment efficacy. BMJ Evid Based Med. 2022;27:153–5. https://doi.org/10.1136/bmjebm-2020-111573.CrossRefPubMed

Mehmi A, Jones P, Somani BK. Current status and role of patient-reported outcome measures (PROMs) in endourology. Urology. 2021;148:26–31. https://doi.org/10.1016/j.urology.2020.09.022.CrossRefPubMed

Ratti MM, Gandaglia G, Alleva E, et al. Standardising the assessment of patient-reported outcome measures in localised prostate cancer. Syst Rev Eur Urol Oncol. 2022;5:153–63. https://doi.org/10.1016/j.euo.2021.10.004.CrossRef

Narang GL, Pannell SC, Laviana AA, et al. Patient-reported outcome measures in urology. Curr Opin Urol. 2017;27:366–74. https://doi.org/10.1097/MOU.0000000000000412.CrossRefPubMed

10.

Vasudevan V, Moldwin R. Addressing quality of life in the patient with interstitial cystitis/bladder pain syndrome. Asian J Urol. 2017;4:50–4. https://doi.org/10.1016/j.ajur.2016.08.014.CrossRefPubMed

11.

Bogart LM, Suttorp MJ, Elliott MN, Clemens JQ, Berry SH. Prevalence and correlates of sexual dysfunction among women with bladder pain syndrome/interstitial cystitis. Urology. 2011;77:576–80. https://doi.org/10.1016/j.urology.2010.10.016.CrossRefPubMed

12.

Keller ML, McCarthy DO, Neider RS. Measurement of symptoms of interstitial cystitis. A pilot study. Urol Clin North Am. 1994;21:67–71.CrossRefPubMed

13.

Porru D, Tinelli C, Gerardini M, Giliberto GL, Stancati S, Rovereto B. Evaluation of urinary and general symptoms and correlation with other clinical parameters in interstitial cystitis patients. Neurourol Urodyn. 2005;24:69–73. https://doi.org/10.1002/nau.20084.CrossRefPubMed

14.

Propert KJ, Mayer RD, Wang Y, et al. Responsiveness of symptom scales for interstitial cystitis. Urology. 2006;67:55–9. https://doi.org/10.1016/j.urology.2005.07.014.CrossRefPubMed

15.

Erickson DR, Morgan KC. Nonbladder related symptoms in patients with interstitial cystitis. J Urol. 2001;166:557–62.CrossRefPubMed

16.

Goin JE, Olaleye D, Peters KM, Steinert B, Habicht K, Wynant G. Psychometric analysis of the University of Wisconsin Interstitial Cystitis Scale: implications for use in randomized clinical trials. J Urol. 1998;159:1085–90. https://doi.org/10.1016/S0022-5347(01)63840-0.CrossRefPubMed

17.

O’Leary MP, Sant GR, Fowler FJ, Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology. 1997;49:58–63. https://doi.org/10.1016/S0090-4295(99)80333-1.CrossRefPubMed

18.

Lubeck DP, Whitmore K, Sant GR, Alvarez-Horine S, Lai C. Psychometric validation of the O’Leary-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium. Urol. 2001;57:62–6. https://doi.org/10.1016/S0090-4295(01)01126-8.CrossRefPubMed

19.

Kuo Y-C, Kuo H-C. O’Leary-Sant Symptom Index predicts the treatment outcome for onabotulinumtoxinA injections for refractory interstitial cystitis/bladder pain syndrome. Toxins (Basel). 2015;7:2860–71. https://doi.org/10.3390/toxins7082860.CrossRefPubMed

20.

Huang M-C, Hsieh C-H, Chang W-C, Chang S-T, Lee M-S. Assessment of treatment outcomes of interstitial cystitis with hydrodistention and bladder training by O’Leary-Sant Interstitial Cystitis Symptom and Problem Indices. Taiwan J Obstet Gynecol. 2018;57:718–21. https://doi.org/10.1016/j.tjog.2018.08.019.CrossRefPubMed

21.

Cvach K, Rosamilia A, Dwyer P, et al. Efficacy of clorpactin in refractory bladder pain syndrome/interstitial cystitis: a randomized controlled trial. Int Urogynecol J. 2021;32:1177–83. https://doi.org/10.1007/s00192-020-04652-3.CrossRefPubMed

22.

Kabay S, Kabay S, Sevim M. First-line treatment posterior tibial nerve stimulation in patients with interstitial cystitis/bladder pain syndrome. Cent European J Urol 2021;74:208–14. https://doi.org/10.5173/ceju.2021.0372.CrossRefPubMedPubMedCentral

23.

Nickel JC, Tripp D, Teal V, et al. Sexual function is a determinant of poor quality of life for women with treatment refractory interstitial cystitis. J Urol. 2007;177:1832–6. https://doi.org/10.1016/j.juro.2007.01.060.CrossRefPubMed

24.

Okui N, Okui M, Gambacciani M. Examining vaginal and vulvar health and sexual dysfunction in patients with interstitial cystitis (UNICORN-1 study). Int Urogynecol J. 2022;33:2493–9. https://doi.org/10.1007/s00192-022-05220-7.CrossRef

25.

Parsons CL, Dell J, Stanford EJ, et al. Increased prevalence of interstitial cystitis: previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium sensitivity. Urology. 2002;60:573–8. https://doi.org/10.1016/S0090-4295(02)01829-0.CrossRefPubMed

26.

Victal ML, D’Ancona CAL, Junqueira RG, Carlos da Silva D, Oliveira HC, de Moraes Lopes MHB. Test-retest reliability and discriminant validity for the Brazilian version of “The Interstitial Cystitis Symptom Index and Problem Index” and “Pelvic Pain and Urgency/Frequency (PUF) Patient Symptom Scale” instruments. Transl Androl Urol. 2015;4:594. https://doi.org/10.3978/J.ISSN.2223-4683.2015.11.01.CrossRefPubMedPubMedCentral

27.

Clemens JQ, Calhoun EA, Litwin MS, et al. Validation of a modified National Institutes of Health Chronic Prostatitis Symptom Index to assess genitourinary pain in both men and women. Urology. 2009;74:983–7.e3. https://doi.org/10.1016/j.urology.2009.06.078.CrossRefPubMed

28.

Humphrey L, Arbuckle R, Moldwin R, et al. The Bladder Pain/Interstitial Cystitis Symptom Score: development, validation, and identification of a cut score. Eur Urol. 2012;61:271–9. https://doi.org/10.1016/j.eururo.2011.10.004.CrossRefPubMed

29.

Lorenzo L, Bonillo MA, Arlandis S, et al. Hidrodistensión bajo anestesia más inyección de Onabotulinumtoxin A en pacientes con síndrome de dolor vesical refractario a tratamiento conservador. Actas Urol Esp. 2016;40:303–8. https://doi.org/10.1016/j.acuro.2015.12.011.CrossRefPubMed

30.

Nickel JC, Egerdie B, Davis E, Evans R, Mackenzie L, Shrewsbury SB. A phase II study of the efficacy and safety of the novel oral SHIP1 activator AQX-1125 in subjects with moderate to severe interstitial cystitis/bladder pain syndrome. J Urol. 2016;196:747–54. https://doi.org/10.1016/j.juro.2016.03.003.CrossRefPubMed

31.

Arlandis S, Bonillo MA. [Cystoscopy in the assessment of patients with bladder pain syndrome: results of a national multicenter observational study]. Arch Esp Urol. 2021;74:456–69.

32.

Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4:28–37.PubMed

33.

ICIQ website. ICIQ Retrieved from Website: https://www.Iciq.Net/. 2022.

34.

Wilson KA, Dowling AJ, Abdolell M, Tannock IF. Perception of quality of life by patients, partners and treating physicians. Qual Life Res. 2000;9:1041–52. https://doi.org/10.1023/a:1016647407161.CrossRefPubMed

35.

Propert KJ, Payne C, Kusek JW, Nyberg LM. Pitfalls in the design of clinical trials for interstitial cystitis. Urology. 2002;60:742–8. https://doi.org/10.1016/S0090-4295(02)01775-2.CrossRefPubMed

36.

Nickel JC, Barkin J, Forrest J, et al. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology. 2005;65:654–8. https://doi.org/10.1016/j.urology.2004.10.071.CrossRefPubMed

Titel: Current status of patient-reported outcome measures and other subjective assessment grading tools in bladder pain syndrome
verfasst von: Sabine Uguzova
Patrick Juliebø-Jones
Christian Beisland
Ahsanul Haq
Publikationsdatum: 02.05.2023
Verlag: Springer International Publishing
Erschienen in: International Urogynecology Journal / Ausgabe 8/2023
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-023-05551-z

Risk of overactive bladder after hysterectomy for uterine fibroids

Original Article

The “Aberdeen Home Continence Stress Test”: a novel objective assessment tool for female stress urinary incontinence

Open Access
Original Article

Effect of cognitive–behavioral therapy on sexual self-esteem and sexual function of reproductive-aged women suffering from urinary incontinence

Original Article

The effect of vitamin D on urgent urinary incontinence in postmenopausal women

Original Article

Motivations, psychosocial burdens, and decision-making modes of post-partum women with stress urinary incontinence engaging in pelvic floor physical therapy: a qualitative research

Original Article

Cervical cancer after the Manchester procedure: a nationwide cohort study

Original Article

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Keine eingeschränkten Kassenleistungen bei Schwangerschaft nach IVF

Medikamente in Schwangerschaft und Stillzeit
Nachrichten

Nach privat bezahlter In-vitro-Fertilisation muss die gesetzliche Krankenkasse ein Arzneimittel zum Erhalt der Schwangerschaft bezahlen, so ein Urteil des Sozialgerichts in München.

Medikamente verändern wohl Nährstoffzusammensetzung der Muttermilch

Medikamente in Schwangerschaft und Stillzeit
Nachrichten

Einige Medikamente wie selektive Serotonin-Wiederaufnahmehemmer können offenbar die Makronährstoffzusammensetzung der Muttermilch verändern. Das birgt möglicherweise gesundheitliche Risiken für manche gestillte Kinder.

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

10.01.2025
Mammakarzinom
Nachrichten

Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.

Cannabisextrakt verbessert Antiemese bei Chemotherapie

10.01.2025
Antiemetische Therapie
Nachrichten

Sprechen Krebskranke auf die übliche Antiemese während einer Chemotherapie nicht ausreichend an, lohnt sich möglicherweise eine Behandlung mit Cannabisextrakt. In einer Phase-2/3-Studie ließ sich die antiemetische Response mit einem solchen Extrakt erheblich verbessern.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Current status of patient-reported outcome measures and other subjective assessment grading tools in bladder pain syndrome